Merck Sharp + Dohme Corp.

Benjamin D Sherry

Gang Qian

Ian Mangion

Donald R Gauthier

Tetsuji Itoh

Yang Cao

Yanfeng Zhang

David M Tschaen

Guy R Humphrey

Michel Journet

Ingyu Jeon

Alfred Lee

Michael J McNevin

Joyce Stellabott

Kung-I Feng

Yong Liu

Gary Martin

Scott Schultz

Ryan Cohen

The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.

Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof

The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase, HIV replication and the treatment of human immunodeficiency virus infection in humans.

Process for making reverse transcriptase inhibitors

The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.

Growing community of inventors

New York, NY, United States of America

Benjamin D Sherry